glp-1 compound Compounded GLP-1s Become Illegal, Price Cuts Roll Out GLP-1 receptor agonist 4 |
Description
Click on the arrows at the top of each section to read more
The FDA noted that it had received over 1000 reports of adverse events arising from compounded GLP-1 dosing errors and unapproved ingredients and suggested that such adverse events are likely underreported due to the limited application of federal regulations to state-licensed pharmacies
Includes PREDIMED data and EU health claim context.
this finding should be interpreted cautiously given the retrospective design, active and non-inert comparator, and likelihood of residual confounding
